Launch of the MEDITWIN Consortium: Virtual twins revolutionize medical practice

Launch of the MEDITWIN Consortium: Virtual twins revolutionize medical practice

The MEDITWIN consortium was officially announced on December 11, 2023, in the presence of the French President and renowned partners such as Dassault Systèmes, seven University Hospital Institutes, Nantes University Hospital, Inria, and associated startups. MEDITWIN aims to introduce personalized virtual twins for organs, metabolism and cancer tumors to improve diagnosis and medical care. This ambitious project will be detailed at the PariSanté Campus event on Thursday December 14, in the presence of Industry Minister Roland Lescure.

The MEDITWIN project will focus on seven new medical practices in the fields of neurology, cardiology and oncology, with the creation of seven “virtual health products“. These advances will be deployed on a sovereign industrial cloud platform. Drawing on the global expertise of its partners, including Dassault Systèmes, Nantes University Hospital, and startups such as inHEART, Codoc, Qairnel, and Neurometers, MEDITWIN is building on the success of virtual twins in other industries to revolutionize healthcare.

The five-year project (2024-2029) will receive financial support from the French government as part of France 2030. MEDITWIN aims to industrialize, clinically validate and standardize the use of virtual twins in the medical field. These advances promise to improve the efficiency of care, the quality of multidisciplinary decisions, and the effectiveness and safety of medical practices and interventions. By establishing standards of care in the form of virtualized experiences, MEDITWIN aspires to become a global benchmark for quality of care and to foster advances in medical science.

Prof. Didier Mutter, CEO, IHU Strasbourg
« Digital twins will be essential elements in the medicine of the future, as they will enable treatments to be simulated in order to provide patients with the most beneficial results possible. MEDITWIN is an extraordinary project in terms of its ambition and the challenges to be met, and it’s also a first for the IHU France alliance to bring together on the same project a multidisciplinary biomedical research power unrivalled anywhere in the world. For the IHU Strasbourg, it will be a powerful powerful boost to improve for improving the minimally invasive management of metastatic colorectal cancer, in close collaboration with two of its historical founders, Inria and the University Hospitals of Strasbourg. »

Read the press release of 11/12/2023 (in French):

Prof. Nicolas Padoy awarded €1.95 million ERC grant for ambitious digital surgery project  – CompSURG

Prof. Nicolas Padoy awarded €1.95 million ERC grant for ambitious digital surgery project – CompSURG

IHU Strasbourg Scientific Director and University of Strasbourg Professor, Nicolas Padoy, head of the CAMMA research team, has been awarded the prestigious ERC Consolidator Grant for his project entitled “Computational Methods to Analyse Intra-operative Adverse Events in Surgery at Scale (CompSURG).” The grant, worth 1.95 million euros, will fund his research over a span of five years. By bridging the fields of artificial intelligence and digital surgery, this ambitious project aims to improve surgical safety and, consequently, patient safety.


CompSURG aims to develop a novel computational methodology for analyzing intra-operative adverse events (IAEs) from surgical videos on a large scale. Currently, IAEs are under-reported, hindering their thorough analysis, the establishment of appropriate safety measures, and the development of intraoperative assistance systems to reduce their occurrence. Recent studies have shown that IAEs, while previously considered inconsequential, may in fact be indicative of serious complications and poor surgical outcomes.

Building on these findings, CompSURG will propose a radically new computational approach to improve intra-operative surgical safety, with a specific focus on automatic recognition and analysis of surgical activities and IAEs in endoscopic videos. This will involve developing novel cutting-edge computer vision and machine learning techniques to achieve groundbreaking models of the intricate interactions between surgical tools and anatomy, examine activity patterns and variability on a large scale, and identify critical steps requiring safety measures.

ERC Consolidator Grants are highly competitive awards bestowed upon outstanding researchers regardless of their nationality or age. The sole criterion for selection is scientific excellence. Recipients of the grant should have between seven and twelve years of post-doctoral experience and conduct their research in a public or private research organization located in an EU member state or associated country. The funding primarily supports the employment of researchers and staff to strengthen the recipients’ teams and is awarded for a maximum duration of five years.

The joint IHU – University of Strasbourg CAMMA research team led by Prof. Nicolas Padoy aims at developing new tools and methods based on computer vision, medical image analysis and machine learning to perceive, model, analyze and support clinician and staff activities in the operating room using the vast amount of digital data generated during surgeries. Nested in the IHU building, the team benefits from a unique infrastructure and eco-system with the university hospital and IRCAD.

Université de Strasbourg
“France 2030”: 12 new IHUs created

“France 2030”: 12 new IHUs created

IHU France welcomes this initiative by the French government to promote the unique model of excellence and acceleration of innovation in healthcare

On May 16, 2023, the French President announced the creation of 12 new University Hospital Institutes (IHUs) as part of the France Santé 2030 scheme. The Alliance IHU France, which brings together FOReSIGHT, IHU ICAN, IHU Strasbourg, Institut du Cerveau, Institut Imagine and Liryc, congratulates the newly appointed IHUs and welcomes this government initiative, which validates the strength of the IHU model by extending it to new medical and scientific themes. This reinforcement is part of a shared ambition for innovation and excellence in biomedical research in France.

IHU: accelerating innovation to invent the medicine of the future

Emblematic creations of the Programme d’Investissement d’Avenir (PIA), the IHUs have been given the mission of accelerating innovation in healthcare for the benefit of patients. The rejection of ivory towers, agility and the development of synergies have encouraged the emergence of excellent biomedical innovations and their transfer to the business world.

Created in 2011, the IHUs bring together research, care, development and training in a single location, and are now fully recognized as third-party experimentation centers. The IHUs have become major players in university hospital research, thanks to their scientific excellence, as demonstrated by their attractiveness for competitive research funding. They are also key partners for industrial companies involved in healthcare innovation.

In less than 10 years, the IHUs have achieved tangible results: over 320 patents filed, 18,000 scientific publications, 1,000 new clinical trials, 45 start-ups created, over 600 million euros in co-financing raised, and induced economic development in excess of 1 billion euros, while State investments represent 277 million euros*, i.e. a leverage effect of 5 to 7.

These new IHU and bioclusters will complement the fields of research already covered by the existing institutes: genetic, visual, cardiometabolic and nutritional diseases, central nervous system, cardiac rhythm, image-guided surgery and emerging infections.

IHU France is delighted to welcome the new IHUs:

  • VBHI, Bordeaux, cerebral vascular diseases, IHU
  • Prism, Villejuif, oncology, IHU
  • re-Connect, Paris, hearing disorders, IHU
  • Prometheus, Garches, sepsis, IHU
  • Thema-2, Paris, hematology, IHU
  • Cancers des femmes, Paris, gynecological cancers, IHU
  • Everest, Lyon, liver pathologies, IHU
  • RespirERA, Nice, respiratory pathologies, IHU
  • IMMUN4CURE, Montpellier, immunotherapies, IHU
  • InovAND, Paris, pediatric neurodevelopment, IHU
  • HealthAge, Toulouse, gerontology and aging, emerging IHU
  • Infiny, Nancy, inflammatory bowel diseases, emerging IHU

IHU France is also delighted with the accreditation of 4 new bioclusters, in particular the Brain & Mind biocluster, which brings together three of the Alliance’s IHUs (Institut du Cerveau, Institut de la Vision and Institut Imagine) and two new ones accredited today (InovAND and re-Connect), and the GenoTher biocluster, of which Institut Imagine is a partner.

With the IHU, the French government aims to make France the leading European nation for innovation in healthcare, and to achieve nationally independence in healthcare.

The success of this new call for IHU projects illustrates the effectiveness of the model, now firmly anchored in the medical innovation ecosystem. With these 12 new IHUs, France now has a new capacity to accelerate and innovate in healthcare in priority areas such as complex data mining, personalized care pathway modeling, diagnostic, therapeutic and preventive simulation using digital twins, and disruptive innovations such as gene and cell therapies for patients. The aim of this combined expertise is to multiply diagnostic capabilities, medical and surgical decision support, and treatments.

The challenge now is to make IHU France a tool for meeting international demands and remaining as responsive and competitive as possible, so as to make France the leading European nation for innovation and achieve sovereignty in healthcare.

The Innovation Santé 2030 plan launched by the government was conceived precisely with this ambition, making a commitment in June 2021 to a strong, value-creating industry to bring, with the impetus of the Secrétariat Général pour l’Investissement (SGPI) and the Agence Innovation en Santé (AIS), direct, concrete solutions to patients and the medical community.

About IHU France

Emblematic creations of the “Investissements d’Avenir” program, the IHUs have been given the mission of integrating and accelerating the action processes of hospital and university research, to disseminate biomedical innovations more rapidly to patients and the economic fabric. IHU France brings together the 6 IHUs: FOReSIGHT, ICM (Institut du Cerveau), IHU ICAN, IHU Strasbourg, Imagine (Institut des maladies génétiques) and Liryc (L’institut des maladies du rythme cardiaque), which combine their strengths, initiatives and proposals to accelerate medical innovation in France. The IHUs have demonstrated́ the power of a model of excellence bringing together in a single location all the expertise that enables medical research to be transformed into innovation for the benefit of patients.

* In 2018, the FOReSIGHT IHU was awarded €50 million in funding under the PIA 3 IHU call for projects. In 2019, the 5 other IHUs in the Alliance IHU France were awarded a further 63 million euros.

Event: AI and megadata, how will they revolutionize tomorrow’s medical research and practice?

Event: AI and megadata, how will they revolutionize tomorrow’s medical research and practice?

The Conseil d’État’s study “Artificial Intelligence and Public Action” of August 2022, raised several questions around the use of artificial intelligence (AI) and megadata by public authorities. These issues are particularly important in the healthcare sector, where the most recent technological developments suggest new ways of using data and artificial intelligence, for the benefit of patients.

To address these issues, the Conseil d’État, the CNIL and Alliance IHU France are organizing a day of work and discussion on February 10, 2023, from 9 a.m. to 3:45 p.m., bringing together doctors, researchers, regulators, industrialists and entrepreneurs, and political decision-makers: AI and megadata, how will they revolutionize tomorrow’s research and medical practice?

The debates are accessible to all via the Conseil d’État website.

Creativity management and innovation in healthcare: the IHU Strasbourg model presented at CreaSXB

Creativity management and innovation in healthcare: the IHU Strasbourg model presented at CreaSXB

The IHU model presented at the 13th edition of the Autumn School on Creativity Management

From November 7 to 11 at key locations in Strasbourg and surroundings

Organized by the BETA (Bureau d’Économie Théorique et Appliquée) of the University of Strasbourg and MosaiC, Pôle créativité & innovation – HEC Montréal, the Autumn School in Creativity Management offers a rich and diversified week-long program.

Promoting the acquisition of new knowledge through new practices around creativity in our organizations and our territories, this week-long training event draws on the real-life skills of its participants: entrepreneurs, executives, decision-makers, managers, creators from various fields of activity, general management, marketing, innovation and R&D managers, young entrepreneurs and associates.

Jean-Luc Dimarcq, Director of Development of the IHU, will speak on the subject of the IHU’s ‘original models to boost innovation in health’ on Wednesday, November 9 at 2pm at the European Doctoral College, 46 Boulevard de la Victoire, Strasbourg.

Find all the information here:
Register here:

L’IHU Strasbourg is awarded one of the 13 Experimental Authorizations from ARCEP for its 5G-Connected Operating Room Project

L’IHU Strasbourg is awarded one of the 13 Experimental Authorizations from ARCEP for its 5G-Connected Operating Room Project

As part of the Government’s 5G Mission entrusted to Philippe Herbet, the Electronic Communications, Postal and Print media distribution Regulatory Authority (Arcep) authorized on October 12 the experimentation in the 3.8 – 4.0 GHz band at the IHU Strasbourg in order to promote access to 5G for industrialists and “vertical” players (local authorities, universities, research laboratories, etc.).

The IHU has been granted one of the 13 experimental authorizations issued by Arcep, covering various sectors of the economy: industry, energy and health.

The thirteen experimental authorizations in the 3.8 - 4.0 GHz band as of October 12, 2022 (Source: Arcep)

The thirteen experimental authorizations in the 3.8 – 4.0 GHz band as of October 12, 2022 (Source: Arcep)


Strasbourg University-Hospital Institute (IHU)

A part of the Franco-German “5G-OR” project, the experiment aims to create the first demo of a new generation of operating room communicating within a private 5G network, for personalized and secure minimally invasive interventions, with the objective of improving patient benefit. The French team involves two institutes created by the Investissements d’Avenir program – the Strasbourg University Hospital Institute and the b<>com Technological Research Institute, as well as the innovative company RDS Diagnostics.